Introduction
Perhaps the greatest advance in clinical immunology in the 20th century were immunosuppressive drugs. The development of these drugs allowed the enduring transplantation of organs and tissues and the amelioration and reversal of some autoimmune conditions. Today, the greatest challenge in clinical immunology is no longer the design of better strategies for immunosuppression (although that challenge still exits) but rather the development of approaches to expand immunity, particularly cell mediated immunity (to some extent, humoral immunity can be replaced or expanded by the administration of gamma globulin or immune globulins of various types). Expanding of cell mediated immunity could address the urgent problems posed by acquired immunodeficiency syndrome and the complications of cancer chemotherapy. Expanding cell mediated immunity could also address a set of auto-immune conditions that arise paradoxically in those whose immune systems have been attenuated by aging or by disease. It might also help to address some of the challenges posed by the growing incidence of cancer. While drugs such a 6-mercaptopurine developed to suppress proliferation of cancer cells could be directly applied to suppressing immunity, what agents or strategies might be able to expanding immunity is less clear. However, recent advances in understanding how T cells develop may provide some clues that could be exploited toward this end. T cells are thought to develop independently of B cells. Thus, T and B cells develop in two distinct anatomical places: T cells in the thymus and B cells in the bone marrow. While T cell production which occurred predominantly in youth declines progressively following adolescence, B cells are continuously made throughout life. The distinct anatomical compartments and production kinetics have been interpreted as demonstrating independent lineage, hence the designation of T and B lineage cells [1] . Humans and mice deficient of T cells (e.g. DiGeorge syndrome) do have B cells [2] , and humans and mice that are deficient of B cells do have T cells [3, 4] . These simple observations suggest that at least some cells of each lineage can be produced independently of cells of the other lineage. However, the observations fail to explain why T cell and B cell functions are abnormal in individuals lacking the other cell type. We can now say that enumerating T cells and B cells is not enough to predict function, much less to conclude how each compartment developed. We will discuss below how assumptions about development failed.
T Cell Development
T cells develop in the thymus, mostly in youth, and the thymus atrophies dramatically with age. In mice, T cells are generated exclusively after birth [5] while in humans T cell development starts in the fetal period [6] . In the thymus, immature T cells undergo a series of developmental steps. The progress of maturation is usually defined based on cell surface expression patterns of CD4 and CD8 receptors. The most primitive thymocytes do not express CD4 or CD8 and are hence designated as doublenegative. As development of thymocytes proceeds, CD4 and CD8 are both expressed, and hence thymocytes at the next stage are said to be double-positive. Next, thymocytes lose expression of either CD4 or CD8, and hence they become positive for one or the other and are called single-positive thymocytes [7] . Development not only yields a mature phenotype, it also assures that the mature cells can contribute to cell mediated immunity. T cells recognize foreign but not self-peptides embedded in MHC class I or II molecules. Hence, one result of T cell development must be the production of a 'repertoire' of T cells that is diverse enough to anticipate a vast number of foreign peptides presented in the context of self-MHC but, at the same time, is not auto-reactive. The complexity of this task can be appreciated if one considers, that i) assembly of the T cell receptor (TCR) genes generates molecules potentially capable of binding to any imaginable conformation of MHC and peptide, and ii) the conformations of self-MHC that mature T cells are desired to recognize (self-MHC + foreign peptide) are not present during development.
The generation of a functional T cell repertoire is achieved in the thymus by coupling random rearrangement of TCR gene segments to a stringent selection pressure, limiting the survival of nascent T cells to those that bind conformations of self-MHC and self-peptides not too well. T cells that bind self-MHC and peptide too well or too poorly die. The thymocytes selected to survive (positively selected) form the mature repertoire of T cells after they emerge from the thymus [8] [9] [10] [11] . The diversity of the TCR repertoire and the probability that selected T cells can recognize and bind a given foreign peptide presented by self-MHC is thus directly related to the number of different self-MHC conformations that mediate selection. Given that the MHC shape is determined to a great extent by the bound peptide [12] , peptide diversity determines the variety of MHC conformations available to select thymocytes. Thus, T cells that mature in mice expressing a single peptide associated with MHC class II are cross-reactive (less restricted) and more frequently alloreactive than T cells that mature in a normal environment with diverse peptides [8, 13] . The nature and properties of the cells that present those peptides are important variables in the generation of T cell diversity by diverse peptides. In the thymus, there are various cells capable of presenting peptides, and for many years thymic epithelial cells were considered largely responsible for this function [14] . However, it could be shown that thymocyte selection did not depend only on the thymic epithelium [15] . What other cells might present peptides to developing thymocytes has, until recently, been unknown. As suggested by our recent work, those other cells may include B cells. There is reason to think that cells of bone marrow origin such as B cells might provide some of the MHC and/or peptide used by thymocytes during development. B cells comprise 1% of thymocytes [16, 17] and are located mostly at the corticomedullary junction [16, 18] where selection takes place. Thymic B cells may participate in negative selection of thymocytes; thus, thymic B cells injected into thymi of neonatal mice promote deletion of auto-reactive thymocytes that recognize the B cells' MHC or superantigens of endogenous murine mammary tumor viruses [19, 20] and also delete superantigen reactive thymocytes in vitro [21] . However, B cells are not required for T cell negative selection because B cell deficient mice delete superantigen reactive T cells [22] . While most B cells in the thymus are mature and have an activated phenotype [17, 21, 23] , B cell progenitors can also be found [16, 24, 25] . While in the mouse the proportion of B cells in the thymus remains constant from birth to 150 days of age, the number of precursor B cells expressing the stem cell marker c-kit decreases with age more than 100-fold [26] , suggesting that these thymic B cell precursors may have a function in youth, perhaps by contributing to T cell development by means other than antigen presentation.
Monoclonal B Cells Counteract Negative Selection of Transgenic T Cells
To study whether and how B cells might interact with T cells, we developed strains of mutant mice with defined populations of B cells and T cells. Mice with monoclonal T cells expressing the DO 11.10 (DO) TCR (DO-T) which recognize a peptide of ovalbumin in the context of MHC class II d were interbred with monoclonal B cell mice [27, 28] . We studied the development of DO-T cells in mice with and without monoclonal B cells, the monoclonal B-T and the monoclonal T mice, respectively [29] . In the monoclonal T mice, the DO-T cells are deleted in the thymus by binding to MHC class II b presenting nominal endogenous peptides, and these have only rare conventional CD4+ T cells in the periphery. In contrast, monoclonal B-T mice had 36-fold more CD4+ T cells in the spleen and at least 2-fold more CD4+ cells in the thymus than monoclonal T mice [29] . These findings suggested that the monoclonal B cells might have promoted T cell development [18] by counteracting negative selection.
B Cell Diversity Is Required for the Development of a Diverse T Cell Repertoire
As indicated by our findings, monoclonal B cells rescue T cells from negative selection, suggesting that B cells enhance survival of developing thymocytes [29] by promoting positive selection ( fig. 1) [18] . Thus, if B cells promote positive selection of thymocytes, both thymocyte numbers and the TCR repertoire diversity should be decreased in B cell deficient mice. Consistent with that prediction, we found that B cell deficient mice have reduced numbers of thymocytes, affecting equally all stages of T cell development (CD4 and CD8 double-negatives, CD4 and CD8 double-positives, CD4 single-positives and CD8 single-positives). Because positive selection requires expression of a functional TCR, the decrease of the number of CD4 and CD8 double-negative T cells lacking such a functional TCR indicates that B cells may influence the development of T cells prior to selection. In order to test whether B cells also promote diversification of the T cell repertoire, we quantified TCR diversity, taking advantage of a novel method developed by Ogle et al. [30] . TCR diversity, primarily determined by V(D)J recombination [31] , decreases progressively during development in the thymus since immature thymocytes (as many as 95%) that fail to express TCR or that express a TCR that binds too strongly or too weakly to MHC die. Since death by neglect and failure of positive selection predominates over death due to negative selection [32] , we reasoned that diversity of the TCR repertoire directly reflects the efficiency of positive selection. Consistent with the possibility that B cells promote positive selection, we found that B cell deficient mice have a million-fold contraction of the thymocyte repertoire compared with wild type [33] . However, our findings indicating that B cells and/or their products promote diversification of the TCR repertoire did not exclude decreased negative selection as a possible mechanism. B cells might promote positive selection by providing a source of diverse peptides. Peptides might be generated from the variable regions of immunoglobulin molecules or from proteins expressed in the periphery. These petides might be captured by B cells and transported to the thymus, just as B cells transport some antigens to lymph nodes. Because T cell diversity in B cell deficient mice is restored by administration of polyclonal immunoglobulin, B cells might promote the positive selection of T cells by providing diverse peptides that otherwise would not be found in the thymus [33] . B cells might also contribute to negative selection although the absence of autoimmunity in B cell deficient mice or in mice with oligoclonal B cells does not favor a critical role of B cells in negative selection. Fig. 1 . B cells and thymocyte selection. T cell development starts with seeding of the thymus at the corticomedullary junction by hematopoietic precursors. Early T cell committed cells lack expression of TCR, CD4 and CD8 and are denominated double-negative (DN) thymocytes. As they mature, DN thymocytes migrate toward the cortex and assemble the TCR genes. Thymocytes that fail to produce functional TCR die by neglect. TCR expression drives proliferation and expression of CD4 and CD8 markers originating double-positive (DP) thymocytes. Whether DP thymocytes mature into CD4 or CD8 single-positive (SP) cells depends on the interaction affinity of the TCR with MHC plus endogenous peptide. Thymocytes expressing a TCR that binds to MHC plus self-peptide with intermediate affinity survive, i.e. are positively selected, whereas if the interaction is too weak or too strong they undergo death by neglect or negative selection, respectively. Positive selection of thymocytes has been generally attributed to thymic epithelial cells. However, our own work suggests that B cells (B) may also promote positive selection. B cells were shown to promote negative selection to viral superantigens (see text). To what extent the functioning of T cells actually depends on the diversity of the TCR repertoire has been difficult to ascertain. Undoubtedly the TCR repertoire is abnormal in acquired immunodeficiency [34] ; however, the defects in T cell function could also be caused by a lack of CD4+ T cells or functional defects in existing T cells rather than by a decreased TCR repertoire. A primary decrease in the T cell repertoire with normal numbers of T cells predicts defective T cell priming in response to antigens that may be recognized by very infrequent T cells (1 in 5 × 10 4 to 1 in 10 5 ), such as minor histocompatibility antigens and protein antigens other than MHC [35] . Corroborating this idea, Linton and collaborators [36] found a decreased frequency of antigen specific CD4+ T cells as early as 5 days after priming with keyhole limpet hemocyanin in B cell deficient mice. On the other hand, one would expect that responses to allogeneic MHC, which can be recognized by up to 10% of T cells [37] , should be relatively unaffected by B cell deficiency and contracted T cell repertoires. Consistent with this prediction, the classical studies in B cell deficient chickens reveal normal rates of rejection of MHC disparate grafts, even though delayed type of hypersensitivity responses are impaired [38] . B cell dependent positive selection of T cells could affect their functioning independently of effects on the repertoire per se. B cells may enhance selection of restricted T cell clones relatively to more promiscuous ones. Thus, in situations where positive selection is compromised, e.g. by immunoglobulin oligoclonality, T cells may be more cross-reactive. Cross-reactive T cells predict relatively unimpaired T cell primary responses and increased frequency of alloreactive T cells. The predictions are consistent with our experimental observations showing that skin allografts are rejected by B cell oligoclonal mice as fast as by wild type mice.
Conclusion
Loss of cell mediated immunity poses one of the greatest challenges in modern medicine and drug development. Acquired immunodeficiency syndrome, chronic immunosuppression, and cancer chemotherapy provide the most dramatic examples. However, loss of cell mediated immunity with aging and due to various auto-immune diseases is the most prevalent. These problems impel those interested in clinical immunology to focus on strategies for building up immunity, especially cell mediated immunity. Most efforts to enhance cell mediated immunity have been directed at the development of improved adjuvants (chemicals that activate antigen presenting cells) or antigenic substances. But if the problem is caused by a limited number or specificity of T cells available to respond, the more effective strategy would be increasing the production of new T cells. Toward that end, we have reviewed certain recent insights from our own work, suggesting that B cells and B cell products might yield a new set of therapeutics to address the vexing challenge of defects in cell mediated immunity.
